DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cerebrotendinous xanthomatosis", "27-hydroxylase deficiency", "CYP27 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Blinded CDCA 250 mg TID; Blood tests; CDCA; CDCA Weight-Based Dose TID; Chenodeoxycholic Acid; Chenodeoxycholic acid; FPF1011; Lovastatin; Open-Label CDCA 250 mg TID; Rescue Medication CDCA 250 mg TID

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004346 (ClinicalTrials.gov)	January 1996	18/10/1999	Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis	Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)	Cerebrotendinous Xanthomatosis	Drug: chenodeoxycholic acid;Drug: lovastatin	National Center for Research Resources (NCRR)	Oregon Health and Science University	Recruiting	N/A	N/A	Both	5	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00004346
(ClinicalTrials.gov)

January 1996

18/10/1999

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)

Cerebrotendinous Xanthomatosis

Drug: chenodeoxycholic acid;Drug: lovastatin

National Center for Research Resources (NCRR)

Oregon Health and Science University

Recruiting

N/A

Both

Phase 2

United States